Cyted Health Secures $44 Million in Series B Financing to Accelerate US Expansion

Cyted Health, a leading gastrointestinal (GI) molecular diagnostics company, led by Marcel

Gehrung, Neha Goel, Prof. Rebecca Fitzgerald, Dr Maria O’Donovan, Sarah Killcoyne, Dr Keith Fiman, Betsy Hanna, Richard Hardwick, and others, has secured $44 million in its Series B financing round led by EQT Life Sciences, investing through its EQT Health Economics strategy, and co-led by Advent Life Sciences and British Business Bank with continued support from existing investors Morningside and BGF. 

The financing will accelerate Cyted’s US commercial expansion, strengthen its UK market presence, and broaden its portfolio of advanced diagnostic tests. The company’s platform includes EndoSign®—an FDA 510(k)-cleared device for minimally invasive esophageal cell collection—and advanced biomarker testing for early detection of esophageal conditions.

Cyted’s technology has seen strong adoption within the UK’s National Health Service, with over 35,000 tests completed and a growing portfolio of peer-reviewed publications demonstrating unmatched patient acceptability and real-world clinical impact. Esophageal cancer remains one of the deadliest cancers worldwide, with survival rates of just 20%.

Founded by leading experts at the University of Cambridge, Cyted is pioneering minimally invasive cell collection combined with proprietary biomarker discovery to transform the detection of pre-cancerous, cancerous, and inflammatory esophageal conditions. The Series B financing follows the launch of the DETECT-ME clinical validation study, which has been enrolling patients across multiple US sites since March 2025. The study aims to validate the clinical performance of Cyted’s latest assays and molecular tests using EndoSign®.